A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups

Ritzmann, Timothy A.; Rogers, Hazel A.; Paine, Simon M.L.; Storer, Lisa C.D.; Jacques, Thomas S.; Chapman, Rebecca J.; Ellison, David; Donson, Andrew M.; Foreman, Nicholas K.; Grundy, Richard G.

doi:10.1002/pbc.28426

All Outputs (3)

Epen-23. A computational analysis of the tumour immune microenvironment in paediatric ependymoma (2020)
Journal Article

Ependymoma is the third commonest childhood brain tumour. Relapse is frequent, often fatal and current therapeutic strategies are inadequate. Previous ependymoma research describes an immunosuppressive environment with T-cell exhaustion, indicating a... Read More about Epen-23. A computational analysis of the tumour immune microenvironment in paediatric ependymoma.

Epen-22. Single-cell RNA sequencing identifies upregulation of IKZF1 in PFA2 myeloid subpopulation driving an anti-tumor phenotype (2020)
Journal Article

We have previously shown immune gene phenotype variations between posterior fossa ependymoma subgroups. PFA1 tumors chronically secrete IL-6, which pushes the infiltrating myeloid cells to an immune suppressive function. In contrast, PFA2 tumors have... Read More about Epen-22. Single-cell RNA sequencing identifies upregulation of IKZF1 in PFA2 myeloid subpopulation driving an anti-tumor phenotype.

A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups (2020)
Journal Article

Background: Relapse occurs in 50% of pediatric ependymoma cases and has poor prognosis. Few studies have investigated the clinical progress of relapsed disease, and treatment lacks a standardized approach. Methods and materials: We analyzed 302 pedia... Read More about A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.